Tim Kutzkey Acquires 12,470 Shares of Surrozen (NASDAQ:SRZN) Stock

Surrozen, Inc. (NASDAQ:SRZN) Director Tim Kutzkey acquired 12,470 shares of Surrozen stock in a transaction that occurred on Tuesday, January 13th. The shares were bought at an average price of $19.80 per share, with a total value of $246,906.00. Following the transaction, the director directly owned 996,502 shares in the company, valued at approximately $19,730,739.60. This trade represents a 1.27% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Tim Kutzkey also recently made the following trade(s):

• On Wednesday, January 14th, Tim Kutzkey bought 5,523 shares of Surrozen stock. The stock was bought at an average cost of $19.99 per share, for a total transaction of $110,404.77.
• On Tuesday, January 6th, Tim Kutzkey purchased 15,100 shares of Surrozen stock. The shares were purchased at an average cost of $19.89 per share, with a total value of $300,339.00.
• On Friday, December 5th, Tim Kutzkey purchased 30,884 shares of Surrozen stock. The shares were purchased at an average price of $19.54 per share, with a total value of $603,473.36.
• On Thursday, December 4th, Tim Kutzkey acquired 5,266 shares of Surrozen stock. The stock was purchased at an average cost of $17.35 per share, for a total transaction of $91,365.10.
• On Thursday, November 13th, Tim Kutzkey acquired 315,457 shares of Surrozen stock. The stock was purchased at an average price of $12.65 per share, for a total transaction of $3,990,531.05.

Surrozen Stock Performance

NASDAQ SRZN opened at $20.00 on Friday. The company has a 50-day moving average price of $18.70 and a two-hundred day moving average price of $13.92. Surrozen, Inc. has a 52 week low of $5.90 and a 52 week high of $24.94. The stock has a market cap of $171.40 million, a price-to-earnings ratio of -0.90 and a beta of 0.58.

Surrozen (NASDAQ:SRZN) last released its quarterly earnings results on Friday, November 7th. The company reported ($3.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($2.44). Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. The business had revenue of $0.98 million for the quarter. As a group, equities research analysts expect that Surrozen, Inc. will post -8.49 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Surrozen to a “sell” rating in a research report on Friday, November 28th. Finally, Lifesci Capital upgraded shares of Surrozen to a “strong-buy” rating in a research report on Thursday, November 13th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Citadel Advisors LLC grew its holdings in Surrozen by 32.8% during the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock worth $179,000 after acquiring an additional 3,424 shares during the period. Geode Capital Management LLC boosted its position in shares of Surrozen by 22.6% during the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after purchasing an additional 5,702 shares in the last quarter. Armistice Capital LLC acquired a new position in shares of Surrozen in the 2nd quarter worth approximately $536,000. Woodline Partners LP bought a new stake in shares of Surrozen in the 3rd quarter worth approximately $621,000. Finally, Schonfeld Strategic Advisors LLC acquired a new position in Surrozen in the third quarter worth approximately $889,000. Institutional investors own 66.57% of the company’s stock.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.